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Hiutung ChuEditorial summary
Recent studies have identified links between host
genetic variants and microbial recognition of the
microbiome. Defects in host–microbiome interactions
in individuals harboring inflammatory bowel disease
risk alleles may result in imbalances of the microbial
community, impaired pathogen clearance, and failure
to sense beneficial commensal microbes. These findings
highlight the importance of maintaining bi-directional
communication at the mucosal interface during
intestinal homeostasis.Thus, the heterogeneity of the microbial composition andGene–environment interactions in inflammatory
bowel disease
Inflammatory bowel disease (IBD), encompassing Crohn’s
disease (CD) and ulcerative colitis (UC), is an idiopathic,
chronic intestinal inflammatory disease involving complex
interactions between genetic and environmental factors.
There is significant variability in symptoms and clinical
manifestations, which may partly reflect the genetic het-
erogeneity of IBD susceptibility. Indeed, close to 200 IBD
susceptibility genes have been identified thus far, though
the lack of complete penetrance indicates that additional
unknown factors are likely to be involved in pathogenesis
[1]. Among the susceptibility genes are those involved in
intestinal barrier function, innate immune recognition of
microbial ligands, antigen presentation, T-cell immunity,
autophagy, and other immune-mediated pathways [1].
The interplay between the gut epithelium and the
microbiota has also been implicated as a contributing fac-
tor in disease pathogenesis, whereby aberrant interactions
may result in inflammatory responses to commensal
microbes [1]. It has become understood that the compos-
ition of the microbiota is important in directing both theCorrespondence: hiuchu@caltech.edu
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cific beneficial microbes can promote immune homeosta-
sis and mucosal tolerance to dampen inflammation [2]. In
IBD, reduced diversity of the microbiota has been
observed, with enrichment of pro-inflammatory microbes
and depletion of anti-inflammatory bacteria. While the
gut microbiome is acquired from birth, and stabilizes in
the first years of life [3], it also serves as an environmental
sensor that interacts with the host to influence immune
phenotypes. Moreover, the composition of the microbiota
can be influenced by a variety of environmental factors,
including diet [3], on both short and long timescales.
its shifts at taxonomic and functional levels, may serve as
another variable in clinical manifestations, highlighting
the complex interaction between host genetics and the
microbiota. Recently, progress has been made in the iden-
tification of novel genetic variants associated with IBD
and in understanding their relationship with the gut
microbiome, revealing that the maintenance of bidirec-
tional communication at the mucosal interface is critical
for sustaining intestinal homeostasis.The role of host genetics in shaping the
microbiota
The relationship between host genetics and the compos-
ition of the gut microbiota has been explored extensively
[4, 5]. The heritability of the microbiome, and its subse-
quent contribution to host health, is governed both by
extrinsic factors (for example, mode of delivery, breast-
feeding, diet) and by host genetics. A recent study exam-
ined the fecal microbiota of over 400 twin pairs and
revealed that monozygotic twins harbored more similar
microbiomes than dizygotic twins, suggesting heritability
of specific taxa within the microbiome [6]. In mouse
models, knockouts of genes linked to IBD have demon-
strated significant shifts in the microbial communities in
the gut, termed dysbiosis, supporting the notion that hostle is distributed under the terms of the Creative Commons Attribution 4.0
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Nucleotide-binding oligomerization domain-containing
protein 2 (NOD2), a cytosolic innate immune pattern
recognition receptor and the first CD susceptibility gene
identified, has been reported to play key roles in maintain-
ing intestinal homeostasis through its detection of pep-
tidoglycan from the microbiota. A large body of evidence
has revealed a role for NOD2 in shaping the composition
of the gut microbiota in IBD patients as well as in animal
models [7], with a recent report showing that the gut
microbiota is altered in Nod2−/− mice, specifically with
an expansion of Bacteroides vulgatus, a pathobiont [8].
The gene encoding caspase recruitment domain 9
(CARD9), another CD susceptibility gene whose product
interacts with NOD2, was recently found to impact the
gut microbiota, whereby Card9−/− mice harbor a more
pro-inflammatory population of microbes with impaired
tryptophan metabolism [9]. Tryptophan metabolites gen-
erated by the microbiota have been shown to be important
in the mucosal immune response, and activation of the
aryl hydrocarbon receptor (AhR) by tryptophan metabo-
lites can direct the production of IL-22, a cytokine import-
ant in intestinal homeostasis. Transfer of the microbiota
from Card9−/− mice into wild-type germ-free mice re-
sulted in increased susceptibility to colitis, delayed recov-
ery from disease, and reduced IL-22 responses compared
to wild-type controls [9]. Accordingly, supplementation
with tryptophan-metabolizing Lactobacillus strains was
sufficient to rescue susceptibility to colitis. These and
other findings clearly show that innate immune sensors
and response regulators, such as NOD2 and CARD9,
respectively, limit the expansion of disease-promoting
microorganisms in the gut, allowing beneficial microbes
to thrive, and thus contribute to host health.
Understanding how genetic variants are involved
in microbial sensing in IBD
The close interaction between the host and the micro-
biota involves the shaping of the microbiota by the host
and concurrent signaling from commensal microbes
through immune-mediated recognition receptors to pro-
mote host tissue and immune development [2]. Main-
taining this bidirectional communication is critical for
supporting intestinal homeostasis. Yet, defects in host
signaling pathways may result in increased susceptibility
to microbial infections while at the same time may
disrupt the fundamental interactions with the indigenous
commensal microbes. Indeed, genome-wide association
studies (GWAS) have identified susceptibility genes
involved in immune signaling pathways [1]. As described
above, NOD2 is involved in bacterial sensing and patho-
gen surveillance during health and disease. IBD patients
harboring risk variants for NOD2 are believed to be
impaired in bacterial recognition and clearance, resultingin sustained intestinal inflammation—a notion supported
by studies of Nod2−/− mice in response to bacterial
infections [7]. Furthermore, NOD2 stimulation has been
shown to activate autophagy, a conserved cellular path-
way involved in the clearance of intracellular microbes
[1, 7]. GWAS have also identified a link between au-
tophagy and IBD, with autophagy pathway genes
ATG16L1 (autophagy-related 16 like 1) and IRGM (im-
munity-related GTPase M), along with NOD2, being
associated with CD susceptibility [1]. Knockout mouse
models for the genes Atg16l1, Irgm, or Nod2 have all
been reported to be impaired in pathogen clearance.
Moreover, defects in ATG16L1 result in diminished se-
cretion of antimicrobial peptides from abnormal Paneth
cells and reduced antigen presentation—all features
that may contribute to IBD pathogenesis [1].
In addition to the detection and clearance of intracellu-
lar pathogens, we recently revealed a role for ATG16L1
and NOD2 in sensing immunomodulatory commensal
bacteria to promote tolerogenic immune responses to
maintain intestinal homeostasis. Mouse dendritic cells
deficient in either Atg16l1 or Nod2 were unable to induce
regulatory T-cell responses to suppress mucosal inflam-
mation upon treatment with Bacteroides fragilis, both
in vitro and during experimental colitis [10]. Furthermore,
immune cells from patients harboring the ATG16L1 risk
allele T300A were unable to respond to B. fragilis in vitro
compared to immune cells carrying the protective T300
allele, indicating that a functional ATG16L1 protein is
required for the induction of anti-inflammatory responses
by immunomodulatory bacterial molecules. Therefore, in
addition to their role in bacterial clearance, we have
proposed a complementary role for ATG16L1 and NOD2,
in which these immune pathways also participate in the
sensing of beneficial microbes [10]. Our work suggests
that patients carrying risk alleles of IBD susceptibility
genes may be cumulatively affected, first in sensing and
clearance of intracellular microbes, and second in the rec-
ognition of immunomodulatory bacterial molecules from
the gut microbiota to promote immune tolerance. Collect-
ively, dysbiosis of the microbiome and the loss of beneficial
commensal microbes, along with impairments in these
IBD susceptibility genes, may lead to chronic, sustained
mucosal inflammation, contributing to IBD pathogenesis.
Conclusions
While host genetics and the gut microbiome have separ-
ately been considered to be contributing factors to host
health and disease in various immune-mediated patholo-
gies, it is now clear that the synergism between these two
players is key to our understanding of the pathogenesis of
IBD. The intestinal microbial community has evolved
alongside the host, contributing to immunity and energy
metabolism [2]. Emerging studies have revealed that a
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important in maintaining intestinal homeostasis. However,
dysbiosis may result in a loss of microbial functional path-
ways important in the production of bacterial metabolites,
such as tryptophan [9], short chain fatty acids (SCFAs),
and other compounds with anti-inflammatory activities to
regulate intestinal inflammation [1]. Specifically, IBD
patients have lower levels of tryptophan and SCFAs in
serum and fecal samples [9]. Further work is necessary to
determine if these bacterial metabolites may serve as bio-
markers for IBD, and if supplementation of these missing
bacterial populations (as probiotics) and/or metabolites
may be sufficient to serve as a potential IBD therapy.
Exploring gene–gut microbiome interactions may
uncover novel strategies for early diagnosis and treatment
of IBD. As probiotics and fecal microbiota transplant
therapies become increasingly prevalent for IBD treatment,
there is also a need to understand the mechanisms by
which host immune pathways integrate microbiome-
derived signals to promote intestinal homeostasis. Under-
standing whether individuals carrying risk alleles associated
with IBD are receptive to the beneficial effects of microbial
therapies will facilitate personalized approaches to treat-
ment. The implications of the microbiome on precision
medicine may be an important consideration for treatment
of IBD and other immune-mediated diseases. In fact,
recent studies have shown that the gut microbiome can
predict patient responsiveness to immunomodulatory ther-
apies, including both chemotherapies and an anti-integrin
therapy (vedolizumab) used in IBD [11]. A personalized
medicine approach that takes into consideration both host
genetics and the gut microbiome could serve to predict
therapeutic responses in the treatment of IBD and
other immune-mediated diseases. Furthermore, future
studies to identify novel pathways and their interactions
with microbial communities could provide targets for
more effective therapies and a better understanding of
the pathogenesis of IBD.
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